SmithKline Paxil "Late Listed" Patents Questioned By Apotex
FDA should de-list from the Orange Book two "late-listed" patents to SmithKline Beecham's Paxil NDA, Apotex requested in a Feb. 3 citizen petition to FDA.
FDA should de-list from the Orange Book two "late-listed" patents to SmithKline Beecham's Paxil NDA, Apotex requested in a Feb. 3 citizen petition to FDA.